This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Diadexus, Inc.. Active years: 2011.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2011
Title: Kenneth R. Shroyer: Innovator in Cancer Treatment
Introduction
Kenneth R. Shroyer is a notable inventor based in Centennial, Colorado. He has made significant contributions to the field of cancer treatment through his innovative work. His research focuses on developing antibody compositions that target specific cancer antigens.
Latest Patents
Kenneth R. Shroyer holds a patent for the invention titled "Ovr110 antibody compositions and methods of use." This invention provides isolated anti-head and neck, ovarian, pancreatic, lung, endometrial, or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The patent also encompasses compositions comprising an anti-Ovr110 antibody and a carrier, which can be provided in an article of manufacture or a kit. Additionally, the invention includes an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Furthermore, it provides cells that produce the anti-Ovr110 antibodies and outlines a method of producing these antibodies. Another aspect of the invention details a method of killing an Ovr110-expressing cancer cell by contacting the cancer cell with an anti-Ovr110 antibody. It also describes a method of alleviating or treating an Ovr110-expressing cancer in a mammal by administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.
Career Highlights
Kenneth R. Shroyer is associated with Diadexus, Inc., where he continues to advance his research in cancer therapies. His work has the potential to significantly impact the treatment of various cancers, providing new avenues for therapeutic interventions.
Collaborations
One of his notable collaborators is Jackie Papkoff, with whom he has worked on various projects related to cancer research and antibody development.
Conclusion
Kenneth R. Shroyer's innovative contributions to cancer treatment through his patented antibody compositions highlight his dedication to advancing medical science. His work continues to pave the way for new therapeutic options in oncology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile